Compare Danaher Corporation (DHR) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Levi Strauss & Co. — how do they compare? Danaher Corporation trades at $198.81 (market cap $140.88B), while Levi Strauss & Co. trades at $23.72 (market cap $9.16B). The key difference: Danaher Corporation is far larger — about 15.4× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays the higher dividend (2.69%). Which is the better fit depends on your goals.
| DHR | LEVI | |
|---|---|---|
Market Cap | $140.88B | $9.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $24.83 |
52-Week Low | $161.91 | $17.92 |
Enterprise Value | $153.66B | $10.47B |
Dividend Yield | 0.8% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
Levi Strauss (LEVI) trades at $24.19, down 0.49% on the day, with a neutral technical signal and strong fundamentals. The company reported Q2 2026 EPS of $0.28, beating estimates of $0.24, and raised full-year guidance. Revenue grew 7.6% year-over-year to $1.56B, driven by direct-to-consumer strength. Valuation metrics show a P/E of 17.28 and P/S of 1.45, with robust profitability including a 61.72% gross margin and 9.66% net margin.
Outlook remains positive with 83% analyst buy ratings and a $28 consensus price target, implying 16% upside. Risks include tariff pressures and foreign exchange volatility noted in recent earnings. The dividend was increased to $0.16, supporting income investors. Continued execution on digital strategy and product expansion provides growth catalysts amid competitive apparel markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
